Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

Tomoki Sakakida,Takeshi Ishikawa,Yusuke Chihara,Sachi Harita,Junji Uchino,Yusuke Tabuchi,Satoshi Komori,Jun Asai,Tsukasa Narukawa,Akihito Arai,Hiroaki Tsunezuka,Toshiyuki Kosuga,Hirotaka Konishi,Michihisa Moriguchi,Hiroaki Yasuda,Fumiya Hongo,Masayoshi Inoue,Shigeru Hirano,Osamu Ukimura,Yoshito Itoh,Tetsuya Taguchi,Koichi Takayama

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

2019

Purpose Immune checkpoint inhibitors (ICIs) show promising clinical activity in advanced cancers. However, the safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies (ANA) are unclear.

Keywords:

Pathology
Blockade
PD-L1
Immune checkpoint
Immunology
Medicine
Anti-nuclear antibody
Atezolizumab
Pembrolizumab
Gastroenterology
Nivolumab
Polymyositis
Durvalumab
Internal medicine
Adverse effect
Dermatomyositis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations